A review of the involvement of Dynamin 2 in cancers sheds light on a promising therapeutic target

Dynamin 2 (DNM2) is a large ubiquitously expressed GTPase, well known for its role in vesicle formation in endocytosis and intracellular membrane trafficking, also acting as a cytoskeletal regulator. In this review of the literature, two researchers from the Myology  Centre for Research* of the Institute of Myology recall that over the past two decades, the involvement of DNM2, via mutations or overexpression, has appeared in a growing number of patients. cancers and often associated with a poor prognosis. A wide range of DNM2-dependent processes have been described in cancer cells, which explains the contribution of DNM2 to the pathological mechanisms of cancer: 

  • DNM2 dysfunction can promote cell migration, invasion and metastasis. 
  • DNM2 has an impact on intracellular signaling pathways promoting proliferation and survival of tumor cells.

In relation to these roles, DNM2 has been shown to be a capable therapeutic target, in a wide range of cancer cells in vitro: 

  • to reduce cell proliferation, 
  • to induce apoptosis
  • to reduce the invasive phenotype

In addition, proof of concept for modulation therapy of DNM2 expression has also been performed in vivo in several animal models. Therefore, DNM2 appears to be a promising molecular target for the development of anti-invasive agents and the proof of concept already provided in animal models represents an important step in preclinical development. 


Team 2- Muscle Organization & Therapy of Dominant Centronuclear Myopathy headed by Marc Bitoun


Trochet D & Bitoun M. A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target. J Exp Clin Cancer Res. 2021 Jul 22;40(1):238. doi: 10.1186/s13046-021-02045-y. PMID: 34294140; PMCID: PMC8296698.